Reference Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
No data available in table

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
No data available in table

Filter rows:

Showing 1 to 37 of 37 entries

Gene	Variant	Impact	Protein Effect	Variant Description
BARD1	R21G	missense	no effect - predicted	BARD1 R21G does not lie within any known functional domains of the Bard1 protein (UniProt.org). R21G demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	P24S	missense	no effect	BARD1 P24S does not lie within any known functional domains of the Bard1 protein (UniProt.org). P24S demonstrates similar homology-directed DNA repair activity (PMID: 39387837), cell growth and apoptosis (PMID: 16061562), genome stability, ubiquitin-conjugation, Brca1 and Rad51 foci formation, and DNA damage response as wild-type Bard1 in cultured cells, and is not transforming in Tp53-null cells in a mouse model (PMID: 33623049).
BARD1	A40V	missense	no effect - predicted	BARD1 A40V lies within the BRCA1-interacting region of the Bard1 protein (UniProt.org). A40V results in a decrease of homology-directed DNA repair activity that is not statistically significant in cell culture in one study (PMID: 30925164), and demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture in another study (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	C74S	missense	no effect - predicted	BARD1 C74S lies within the RING-type zinc finger domain and BRCA1-interacting region of the Bard1 protein (UniProt.org). C74S demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	V85M	missense	loss of function	BARD1 V85M lies within the RING-type zinc finger domain and BRCA1-interacting region of the Bard1 protein (UniProt.org). V85M demonstrates Bard1 subcellular localization and Brca1, Palb2, and Rad51c interaction similar to wild-type Bard1, but results in impaired homology-directed DNA repair activity, decreased DNA repair post-irradiation, decreased H2A ubiquitination, and increased sensitivity to olaparib and cisplatin treatment in cultured cells (PMID: 39387837).
BARD1	M104I	missense	no effect - predicted	BARD1 M104I lies within the BRCA1-interacting region of the Bard1 protein (UniProt.org). M104I demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 30925164, PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	T165S	missense	no effect - predicted	BARD1 T165S lies within the RAD51-interacting domain of the Bard1 protein (PMID: 28976962). T165S demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	P187A	missense	loss of function	BARD1 P187A does not lie within any known functional domains of the Bard1 protein (UniProt.org). P187A results in altered subcellular localization, decreased Brca1, Palb2, and Rad51c interaction, impaired homology-directed DNA repair activity, decreased DNA repair post-irradiation, decreased H2A ubiquitination, and increased sensitivity to olaparib and cisplatin treatment in cultured cells (PMID: 39387837).
BARD1	E193Q	missense	no effect - predicted	BARD1 E193Q lies within the RAD51-interacting domain of the Bard1 protein (PMID: 28976962). E193Q demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	I286V	missense	no effect - predicted	BARD1 I286V does not lie within any known functional domains of the Bard1 protein (UniProt.org). I286V demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	V297I	missense	no effect - predicted	BARD1 V297I does not lie within any known functional domains of the Bard1 protein (UniProt.org). V297I demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	G345E	missense	no effect - predicted	BARD1 G345E does not lie within any known functional domains of the Bard1 protein (UniProt.org). G345E demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	R406L	missense	no effect - predicted	BARD1 R406L does not lie within any known functional domains of the Bard1 protein (UniProt.org). R406L demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	P411S	missense	no effect - predicted	BARD1 P411S does not lie within any known functional domains of the Bard1 protein (UniProt.org). P411S demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	D440G	missense	no effect - predicted	BARD1 D440G lies within ANK repeat 1 of the Bard1 protein (UniProt.org). D440G demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	T490I	missense	no effect - predicted	BARD1 T490I lies within ANK repeat 2 of the Bard1 protein (UniProt.org). T490I demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	G491R	missense	loss of function	BARD1 G491R lies within ANK repeat 2 of the Bard1 protein (UniProt.org). G491R results in decreased interaction with the ubiquitinated nucleosomal core particle (PMID: 34102105), Brca1, Palb2, and Rad51c, impaired homology-directed DNA repair activity, altered subcellular localization, decreased DNA repair post-irradiation, decreased H2A ubiquitination, and increased sensitivity to olaparib and cisplatin treatment in cultured cells (PMID: 39387837).
BARD1	E537K	missense	no effect - predicted	BARD1 E537K lies within degenerate ANK repeat 4 of the Bard1 protein (UniProt.org). E537K demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	R565C	missense	loss of function	BARD1 R565C lies within BRCT domain 1 of the Bard1 protein (UniProt.org). R565C confers a loss of function to Bard1 as demonstrated by decreased homology-directed DNA repair activity in cell culture (PMID: 30925164, PMID: 39387837), altered subcellular localization and decreased DNA repair after irradiation, decreased interaction with Brca1, and increased sensitivity to cisplatin and olaparib treatment in culture (PMID: 39387837).
BARD1	G568E	missense	no effect - predicted	BARD1 G568E lies within BRCT domain 1 of the Bard1 protein (UniProt.org). G568E demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	L570V	missense	no effect - predicted	BARD1 L570V lies within BRCT domain 1 of the Bard1 protein (UniProt.org). L570V demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	Q581K	missense	no effect - predicted	BARD1 Q581K lies within BRCT domain 1 of the Bard1 protein (UniProt.org). Q581K demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	L585I	missense	no effect - predicted	BARD1 L585I lies within BRCT domain 1 of the Bard1 protein (UniProt.org). L585I demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	D601H	missense	no effect - predicted	BARD1 D601H lies within BRCT domain 1 of the Bard1 protein (UniProt.org). D601H demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	T605I	missense	no effect - predicted	BARD1 T605I lies within BRCT domain 1 of the Bard1 protein (UniProt.org). L570V demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	G611S	missense	no effect - predicted	BARD1 G611S lies within BRCT domain 1 of the Bard1 protein (UniProt.org). G611S demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	T617I	missense	no effect - predicted	BARD1 T617I lies within BRCT domain 1 of the Bard1 protein (UniProt.org). T617I demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	M621T	missense	no effect - predicted	BARD1 M621T lies within BRCT domain 1 of the Bard1 protein (UniProt.org). M621T demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	R641Q	missense	no effect - predicted	BARD1 R641Q lies within BRCT domain 1 of the Bard1 protein (UniProt.org). R641Q results in a decrease of homology-directed DNA repair activity that is not statistically significant in cell culture in one study (PMID: 30925164), and demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture in another study (PMID: 39387837), and therefore, its effect on Bard1 protein function is unknown.
BARD1	R658C	missense	unknown	BARD1 R658C does not lie within any known functional domains of the Bard1 protein (UniProt.org). R658C demonstrates effects on Tp53 stability, cell growth and apoptosis (PMID: 16061562), and homology-directed DNA repair activity similar to wild-type Bard1 in one study (PMID: 39387837), but does not bind to or stabilize Nfkb1 p50 (PMID: 33024116), and results in a decrease of homology-directed DNA repair activity that is not statistically significant in cell culture (PMID: 30925164), and therefore, its effect on Bard1 protein function is unknown.
BARD1	P669L	missense	loss of function	BARD1 P669L lies within BRCT domain 2 of the Bard1 protein (UniProt.org). P669L demonstrates Bard1 subcellular localization and Brca1, Palb2, and Rad51c interaction similar to wild-type Bard1, but results in impaired homology-directed DNA repair activity, decreased DNA repair post-irradiation, decreased H2A ubiquitination, and increased sensitivity to olaparib and cisplatin treatment in cultured cells (PMID: 39387837).
BARD1	N690K	missense	no effect - predicted	BARD1 N690K lies within BRCT domain 2 of the Bard1 protein (UniProt.org). N690K demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	L691F	missense	no effect - predicted	BARD1 L691F lies within BRCT domain 2 of the Bard1 protein (UniProt.org). L691F demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	V695D	missense	no effect - predicted	BARD1 V695D lies within BRCT domain 2 of the Bard1 protein (UniProt.org). V695D demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.
BARD1	T719R	missense	loss of function	BARD1 T719R lies within BRCT domain 2 of the Bard1 protein (UniProt.org). T719R demonstrates Bard1 subcellular localization and Brca1, Palb2, and Rad51c interaction similar to wild-type Bard1, but results in impaired homology-directed DNA repair activity, decreased DNA repair post-irradiation, decreased H2A ubiquitination, and increased sensitivity to olaparib and cisplatin treatment in cultured cells (PMID: 39387837).
BARD1	Q730L	missense	loss of function	BARD1 Q730L lies within BRCT domain 2 of the Bard1 protein (UniProt.org). Q730L demonstrates Brca1, Palb2, and Rad51c interaction similar to wild-type Bard1, but results in altered Bard1 subcellular localization, impaired homology-directed DNA repair activity, decreased DNA repair post-irradiation, decreased H2A ubiquitination, and increased sensitivity to olaparib and cisplatin treatment in cultured cells (PMID: 39387837).
BARD1	W762F	missense	no effect - predicted	BARD1 W762F lies within BRCT domain 2 of the Bard1 protein (UniProt.org). W762F demonstrates homology-directed DNA repair activity similar to wild-type Bard1 in culture (PMID: 39387837), and therefore, is predicted to have no effect on Bard1 protein function.

Showing 1 to 37 of 37 entries

Filter rows:

Showing 1 to 42 of 42 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BARD1 G491R	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 G491R was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 G491R	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 G491R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 G491R	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 G491R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 G491R	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 G491R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 G491R	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 G491R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 G491R	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 G491R was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P187A	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 P187A was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P187A	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 P187A was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P187A	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 P187A was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P187A	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 P187A was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P187A	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 P187A was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P187A	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 P187A was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P669L	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 P669L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P669L	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 P669L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P669L	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 P669L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P669L	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 P669L was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P669L	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 P669L was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 P669L	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 P669L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 Q730L	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 Q730L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 Q730L	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 Q730L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 Q730L	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 Q730L was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 Q730L	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 Q730L was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 Q730L	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 Q730L was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 Q730L	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 Q730L was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 R565C	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 R565C was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 R565C	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 R565C was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 R565C	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 R565C was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 R565C	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 R565C was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 R565C	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 R565C was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 R565C	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 R565C was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 T719R	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 T719R was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 T719R	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 T719R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 T719R	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 T719R was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 T719R	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 T719R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 T719R	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 T719R was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 T719R	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 T719R was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 V85M	breast cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 V85M was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 V85M	ovarian cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 V85M was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 V85M	breast cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 V85M was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 V85M	ovarian cancer	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 V85M was sensitive to Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 V85M	breast cancer	sensitive	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line expressing BARD1 V85M was sensitive to Platinol (cisplatin) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837
BARD1 V85M	ovarian cancer	sensitive	Cisplatin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian cancer cell line expressing BARD1 V85M was sensitive to treatment with the combination of Platinol (cisplatin) and Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 39387837).	39387837

Showing 1 to 42 of 42 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting